Exploring new treatments for ovarian cancer linked to ARID1A mutations
Project 3: Investigating new treatment approaches based on DNA repair vulnerability in ARID1A mutated type I ovarian cancer
This study is looking at how changes in the ARID1A gene make ovarian cancer cells struggle to fix their damaged DNA, with the goal of creating new treatments that take advantage of this weakness, and patients may have the chance to try these innovative therapies in upcoming trials.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10935408 on NIH RePORTER |
What this research studies
This research investigates how mutations in the ARID1A gene affect the ability of ovarian cancer cells to repair DNA damage. By understanding the specific vulnerabilities of these cancer cells, the researchers aim to develop targeted treatments that exploit their weakened DNA repair mechanisms. The study will involve analyzing the effectiveness of DNA base excision repair in cancer cells with ARID1A mutations, which could lead to innovative therapeutic strategies. Patients may be involved in trials that test these new treatment approaches.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with type I ovarian cancer, particularly those with ARID1A mutations.
Not a fit: Patients without ARID1A mutations or those with other types of ovarian cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with ARID1A mutated ovarian cancer.
How similar studies have performed: Previous research has shown promise in targeting DNA repair vulnerabilities in cancer, suggesting that this approach could be effective.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Gaillard, Stephanie — Johns Hopkins University
- Study coordinator: Gaillard, Stephanie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.